A D Shapiro
Overview
Explore the profile of A D Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reipert B, Gangadharan B, Hofbauer C, Berg V, Schweiger H, Bowen J, et al.
Blood Adv
. 2020 Nov;
4(22):5785-5796.
PMID: 33232473
Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII...
2.
Shapiro A, Mitchell I, Nasr S
J Thromb Haemost
. 2018 Sep;
16(12):2362-2374.
PMID: 30264916
Bypassing agents are presently the standard of care for the treatment of bleeding episodes in patients with hemophilia and high-titer inhibitors and are also used for bleed prevention. Only two...
3.
Gupta S, Shapiro A
Haemophilia
. 2018 Jun;
24 Suppl 6:76-86.
PMID: 29878655
The focus of care providers, patients and families is the ability to tailor care for persons with haemophilia (PWH) across the lifespan. Care requires knowledge of the bleeding disorder and...
4.
Miller C, Boylan B, Shapiro A, Lentz S, Wicklund B
J Thromb Haemost
. 2017 Aug;
15(10):1971-1976.
PMID: 28795528
Summary: Background The Bethesda assay for measurement of factor VIII inhibitors called for quantification of positive inhibitors by using dilutions producing 25-75% residual activity (RA), corresponding to 0.4-2.0 Bethesda units,...
5.
Doruelo A, Haberichter S, Christopherson P, Boggio L, Gupta S, Lentz S, et al.
J Thromb Haemost
. 2017 May;
15(8):1559-1566.
PMID: 28544236
Summary: Background von Willebrand factor (VWF) is a multimeric coagulation factor that tethers platelets to injured subendothelium. Type 2M von Willebrand disease (VWD) is characterized by a qualitative defect in...
6.
Shapiro A, Mahlangu J, Perry D, Pasi J, Quon D, Chowdary P, et al.
Haemophilia
. 2017 Feb;
23(3):392-399.
PMID: 28220631
Introduction: The Phase 3 A-LONG study demonstrated the safety and efficacy of rFVIIIFc for the control and prevention of bleeding episodes in severe haemophilia A. Aim: To describe the treatment...
7.
Quon D, Klamroth R, Kulkarni R, Shapiro A, Baker R, Castaman G, et al.
Haemophilia
. 2016 Dec;
23(1):e39-e42.
PMID: 27943467
No abstract available.
8.
Kulkarni R, Presley R, Lusher J, Shapiro A, Gill J, Manco-Johnson M, et al.
Haemophilia
. 2016 Nov;
23(2):207-214.
PMID: 27813214
Aim: To describe the prevalence and complications in babies ≤2 years with haemophilia. Methods: We used a standardized collection tool to obtain consented data on eligible babies aged ≤2 years...
9.
Sood S, James A, Ragni M, Shapiro A, Witmer C, Vega R, et al.
Haemophilia
. 2016 Oct;
22(6):e562-e564.
PMID: 27704648
No abstract available.
10.
Shapiro A, White Ii G, Kim H, Lusher J, Bergman G
Haemophilia
. 2016 May;
3(4):247-53.
PMID: 27214859
The present study summarizes results of the efficacy and safety of monoclonal antibody (MAb) purified factor IX concentrate [Mononine® Coagulation Factor IX (Human), Centeon L.L.C., King of Prussia, PA, USA]...